Classifica tra le azioni
#17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Prezzo delle azioni
$0.0416118
Capitalizzazione di mercato
$12.78M
Variazione (1 giorno)
1.72%
Variazione (1 anno)
-22.01%
Scambia Noxopharm Limited (NOX)
Margine operativo per Noxopharm Limited (NOX)
Margine operativo al March 2026 TTM: -532.32%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Noxopharm Limited, il margine operativo attuale (TTM) è -532.32%. Alla fine del 2024, il margine operativo era -313.92%.
Storico del margine operativo per Noxopharm Limited da 2016 a 2026
Margine operativo alla fine di ogni anno
| Anno |
Margine Operativo |
Cambia |
|
2026 (TTM) |
-532.32%
|
55.59%
|
|
2025 |
-342.14%
|
8.99%
|
|
2024 |
-313.92%
|
13.69%
|
|
2023 |
-276.12%
|
-1.43%
|
|
2022 |
-280.14%
|
7.54%
|
|
2021 |
-260.50%
|
31.83%
|
|
2020 |
-197.61%
|
-52.69%
|
|
2019 |
-417.69%
|
-63.54%
|
|
2018 |
-1,145.69%
|
-55.34%
|
|
2017 |
-2,565.11%
|
0.00%
|
|
2016 |
0.00%
|
0.00%
|
Margine operativo per aziende simili o concorrenti
| Azienda |
Margine Operativo |
Differenza del margine operativo |
Il paese |
|
|
41.30% |
-100.08%
|
DK
|
|
|
35.45% |
-100.07%
|
US
|
|
|
24.95% |
-100.05%
|
US
|
|
|
25.32% |
-100.05%
|
BE
|
|
|
25.72% |
-100.05%
|
AU
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.
